LENZ THERAPEUTICS, INC. Deferred Tax Assets, Operating Loss Carryforwards
LENZ THERAPEUTICS, INC. (LENZ) had Deferred Tax Assets, Operating Loss Carryforwards of $38.20 million as of 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-24
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $38.20M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $15.54M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $3.98M; Deferred Tax Assets, Operating Loss Carryforwards as first filed $30.82M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $15.94M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $38.20M 10-K · filed 2026-03-24 | |
| 2024-12-31 | $15.54M 10-K · filed 2026-03-24 | |
| 2023-12-31 | $3.98M 10-K · filed 2025-03-19 | $30.82M 10-K · filed 2024-02-27 |
| 2022-12-31 | $15.94M 10-K · filed 2024-02-27 | |
| 2021-12-31 | $12.01M 10-K · filed 2023-03-20 | |
| 2020-12-31 | $2.27M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |